Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions-Reference-Cited by-同舟云学术

Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions

Published:2019-02-09 Issue:5 Volume:62 Page:2508-2520
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Popow Johannes¹,Arnhof Heribert¹,Bader Gerd¹,Berger Helmut¹,Ciulli Alessio²^ORCID,Covini David¹,Dank Christian¹,Gmaschitz Teresa¹,Greb Peter¹,Karolyi-Özguer Jale¹,Koegl Manfred¹,McConnell Darryl B.¹,Pearson Mark¹,Rieger Maria¹,Rinnenthal Joerg¹,Roessler Vanessa¹,Schrenk Andreas¹,Spina Markus¹,Steurer Steffen¹,Trainor Nicole²,Traxler Elisabeth¹,Wieshofer Corinna¹,Zoephel Andreas¹,Ettmayer Peter¹^ORCID

Affiliation:

1. Boehringer Ingelheim RCV GmbH & Co KG, 1221 Vienna, Austria

2. Division of Biological Chemistry and Drug Discovery, School of Life Sciences, James Black Centre, University of Dundee, Dow Street, DD1 5EH Dundee, Scotland, U.K.

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b01826

Reference52 articles.

1. Targeting FAK in human cancer: from finding to first clinical trials

2. FAK in cancer: mechanistic findings and clinical applications

3. Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma

4. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma

Cited by 108 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders;European Journal of Medicinal Chemistry;2024-10

2. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

3. Focal adhesion kinase signaling – tumor vulnerabilities and clinical opportunities;Journal of Cell Science;2024-07-15

4. FAK inhibitors in cancer, a patent review – an update on progress;Expert Opinion on Therapeutic Patents;2024-07-02

5. A novel FAK-degrading PROTAC molecule exhibited both anti-tumor activities and efficient MDR reversal effects;Acta Pharmacologica Sinica;2024-06-06